Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation
Michael G. Ison, John J. Friedewald – 27 April 2009
Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA–negative patients are associated with virological relapse
Monica Basso, Edoardo G. Giannini, Francesco Torre, Sabrina Blanchi, Vincenzo Savarino, Antonino Picciotto – 27 April 2009 – The incidence and clinical meaning of elevated alanine aminotransferase (ALT) in chronic hepatitis C patients who are hepatitis C virus (HCV)‐RNA negative during pegylated interferon (PEG‐IFN) and ribavirin therapy have not been completely characterized.
Vascular disorders of the liver
Laurie D. DeLeve, Dominique‐Charles Valla, Guadalupe Garcia‐Tsao – 27 April 2009
Hepatitis B: The virus and disease
T. Jake Liang – 27 April 2009 – Hepatitis B virus (HBV) infects more than 300 million people worldwide and is a common cause of liver disease and liver cancer. HBV, a member of the Hepadnaviridae family, is a small DNA virus with unusual features similar to retroviruses. HBV replicates through an RNA intermediate and can integrate into the host genome. The unique features of the HBV replication cycle confer a distinct ability of the virus to persist in infected cells.
The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis
Pei‐Chun Tsai, Tz‐Win Fu, Yi‐Ming Arthur Chen, Tsui‐Ling Ko, Tien‐Hua Chen, Yang‐Hsin Shih, Shih‐Chieh Hung, Yu‐Show Fu – 27 April 2009 – We investigated the effect of human umbilical mesenchymal stem cells (HUMSCs) from Wharton's jelly on carbon tetrachloride (CCl4)–induced liver fibrosis in rats. Rats were treated with CCl4 for 4 weeks, and this was followed by a direct injection of HUMSCs into their livers.
Small size and disease severity in living donation: A difficult match
Kim M. Olthoff – 27 April 2009
Ascites and variceal bleeding occurring in a 20‐year‐old with cystic fibrosis
M. Isabel Fiel, Thomas Schiano – 27 April 2009
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus‐1–hepatitis B virus coinfected individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy
Sharon R. Lewin, Ruy M. Ribeiro, Anchalee Avihingsanon, Scott Bowden, Gail Matthews, Pip Marks, Stephen A. Locarnini, Kiat Ruxrungtham, Alan S. Perelson, Gregory J. Dore – 27 March 2009 – Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus‐1 (HIV‐1) and hepatitis C virus.
MicroRNA‐101 regulates expression of the v‐fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma
Shuai Li, Hanjiang Fu, Yulan Wang, Yi Tie, Ruiyun Xing, Jie Zhu, Zhixian Sun, Lixin Wei, Xiaofei Zheng – 27 March 2009 – MicroRNAs (miRNAs) have recently been proposed as a versatile class of molecules involved in regulation of various biological processes. Although there is emerging evidence that some microRNAs can function as oncogenes or tumor suppressors, the specific role of miRNA in human hepatocellular carcinoma (HCC) is unclear at this point.
High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis
Frank G. Schaap, Niels A. van der Gaag, Dirk J. Gouma, Peter L. M. Jansen – 27 March 2009 – Fibroblast growth factor 19 (FGF19) is an endocrine factor produced by the small intestine in response to uptake of luminal bile salts. In the liver, FGF19 binds to FGF receptor‐4, resulting in down‐regulation of cytochrome P (CYP) 7A1 and reduced bile salt synthesis.